Lowering Intracranial Pressure in Idiopathic Intracranial Hypertension: Assessing the Therapeutic Efficacy and Safety of an 11β-hydroxysteroid Dehydrogenase Type 1 Inhibitor (AZD4017). Phase II Study.
Phase of Trial: Phase II
Latest Information Update: 18 Oct 2018
Price : $35 *
At a glance
- Drugs AZD 4017 (Primary)
- Indications Pseudotumour cerebri
- Focus Therapeutic Use
- Acronyms IIH:DT
- 31 Aug 2018 Biomarkers information updated
- 29 Mar 2017 Status changed from active, no longer recruiting to completed.
- 25 Oct 2016 Planned End Date changed from 1 Aug 2016 to 1 Dec 2016.